Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
Part of paid clinical trials in Beverly Hills, California.
- Sponsor
- Peter A Campochiaro, MD
- Study ID
- NCT01198327
- Phase
- PHASE3
- Status
- Completed
Conditions
- Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ranibizumab — DRUGIntravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
- Peripheral Laser — OTHERAreas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
Study Details
This study evaluates long-term safety in patients with macular edema due to Retinal Vein Occlusion (RVO) originally enrolled in the BRAVO \& CRUISE trials and subsequently followed in the HORIZON extension trial.
Key Dates
- First listed
- Sep 10, 2010
- Start date
- Aug 31, 2010
- Status verified
- Nov 2013
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
Study Design
- Enrollment
- 66 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Ranibizumab as neededIntravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart; with optional peripheral laser to areas of non-perfusion.
Primary Outcome Measure
Incidence of Serious Adverse Events. [ Time Frame: 24 mos ]
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Retina-Vitreous Associates Medical Group | Beverly Hills | California | 90211 | - |
| Retinal Consultants Medical Group | Sacremento | California | 95819 | - |
| Southeast Retina | Augusta | Georgia | 30909 | - |
| Ophthalmic consultants of Boston | Boston | Massachusetts | 02114-2587 | - |
| Retina Associates of New Jersey | Teaneck | New Jersey | 07666 | - |
| Retina Consultants of Houston | Houston | Texas | 77030 | - |
Find similar trials in Beverly Hills, CA
Related Studies
- Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsPHASE4 · Enrolling By Invitation · Harrow Inc · Tyler, Texas
- National Eye Institute Biorepository for Retinal DiseasesRecruiting · National Eye Institute (NEI) · Bethesda, Maryland
- Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein SodiumEARLY_PHASE1 · Recruiting · MediBeacon · Ann Arbor, Michigan
- Optical Coherence Tomography Angiography in Subjects With Retinal Vascular DiseaseRecruiting · Johns Hopkins University · Baltimore, Maryland